About this trial
Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin.
Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease.
Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients .
Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male and female patients diagnosed with vitiligo.
Medically and psychologically stable patients.
Good cognitive abilities to understand the requirements of the study.
All patients enrolled to the study will have their informed consent.
Disqualifiers
Pregnancy or lactation.
Immunosuppression.
Alcohol abuse.
History of spontaneous re-pigmentation of lesions.
Trial design
Parallel
Treatments tested in this trial
Beclomethasone
Drugto determine the effect of betamethasone phonophoresis on vitiligo patients.
Treatment groups
Trial outcomes
Primary outcomes
vitiligo Management
Evaluation of the patients whom suffering from vitiligo and using betamethasone phonophoresis for the treatment of vitiligo using Vitiligo noticeability scale (VNC)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.